New nebuliser set to replace the need for jabs

New nebuliser set to replace the need for jabs

A revolutionary nebuliser developed by RMIT University researchers could one day deliver life-saving cancer drugs and vaccines traditionally given by injection.

Cheap, light-weight and portable, the advanced nebuliser delivers precise drug doses to patients with life-threatening or debilitating lung conditions including cancer, tuberculosis, asthma and cystic fibrosis.

But the Respite(TM) nebuliser also has the potential to be used to administer insulin to people with diabetes or to painlessly vaccinate infants currently subjected to needles.

The patented technology is among 10 RMIT-developed technologies to be showcased in Singapore next week at TechInnovation 2015, a premier industry-to-technology event (September 22-23). 

Professor Leslie Yeo, Director of RMIT's MicroNanophysics Research Laboratory, said the Respite technology had the potential to revolutionise how patients were treated with drugs, including people with whose poor survival rates have stayed stable despite significant therapeutic advances in recent years.

"Anything we can nebulise, we can potentially deliver," Yeo said.

"The problem with normal puffers is that only 30 per cent of the drugs actually get to the lungs, the rest is lost in the mouth – which isn't a problem if the drugs are  cheap but is when they are expensive.

"The most important aspect of our device is that it does not require inhalation to generate the aerosols as with the ubiquitous inhalers, which can be a problem for people already suffering compromised lung function."

Yeo said traditional inhalers also require hand-breath coordination to use and elderly and very young patients must be taught to avoid misusing.

"And unlike one-size-fits-all inhalers, Respite allows the dose to be adjusted based on a patient's size, age, gender, physiological profile and disease severity."

The design does not require meshes or nozzles unlike other nebulisers, so there is no clogging or fouling problems that diminish performance.

The Respite technology uses sound waves to excite the surface of the fluid or drug. This generates a fine mist capable of delivering much larger molecules directly to the lungs.

Rigorous lab tests have proved the device capable of delivering next generation drugs such as proteins, peptides and DNA to the lungs without a patient having to inhale. The device delivers drugs at rates of up to 3 ml/min, compared to the much smaller doses of 0.4 ml/min benchmark of current nebulisers.

Recent trials in Melbourne also showed sheep given a DNA flu vaccine via a nebuliser had comparable immune responses to animals injected with the vaccine.

A Professor of Chemical Engineering and an Australian Research Council Future Fellow, Yeo believes the device has enormous potential, particularly for people with lung cancer.

"The five-year survival rate for lung cancer remains around 15 per cent despite the significant therapeutic advances achieved in recent years and currently, there are no personalised delivery devices for inhaled cancer drugs to improve these clinical outcomes," he said.

"Our nebuliser addresses this gap as a low-cost and convenient yet efficient method of delivering oncolytics directly to the lungs, potentially revolutionising the treatment of lung cancer."

Lung cancer is the most common cancer in the world. 

The nebuliser can also be used for a range of non-pharmaceutical applications such as perfumes, cosmetics and sterilisation of equipment and surfaces.

Other patented RMIT technologies to be featured at TechInnovation 2015 include:

  • Human gas capsule: A small pill for profiling the gases of the gut, offering instant data collection that is sent directly to a smart phone for analysis
  • Just in time implants: A unique patented method for designing and customising orthopaedic implants using 3D technology
  • Anti-turbulence sensor system: A system that can pre-empt and adjust for turbulence well before it can affect an aircraft

Explore further

Driver of non-small cell lung cancer, FGFR1, also in 23 percent of small cell lung cancer

Provided by RMIT University
Citation: New nebuliser set to replace the need for jabs (2015, September 18) retrieved 13 November 2019 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments